{"id":50876,"date":"2026-07-13T21:08:12","date_gmt":"2026-07-13T21:08:12","guid":{"rendered":"https:\/\/www.europesays.com\/france\/50876\/"},"modified":"2026-07-13T21:08:12","modified_gmt":"2026-07-13T21:08:12","slug":"lakefront-announces-paulo-fontoura-has-resigned-from-its-board-following-his-appointment-as-global-head-of-rd-at-sanofi","status":"publish","type":"post","link":"https:\/\/www.europesays.com\/france\/50876\/","title":{"rendered":"Lakefront Announces Paulo Fontoura has Resigned from its Board following his Appointment as Global Head of R&D at Sanofi"},"content":{"rendered":"

Mechelen, Belgium; July 13, 2026, 22:01 CET; Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) today announced that following his appointment as Executive Vice President, Global Head of Research & Development Pharma at Sanofi SA, Dr. Paulo Fontoura has tendered his resignation from the Board of Directors.<\/p>\n

“I want to congratulate Paulo on this important assignment and sincerely thank him for his insight and guidance during his tenure on our Board,\u201d said Gino Santini, Chair of the Board of Directors. “We wish him the best of luck in his new position and we expect to appoint a successor at the earliest practical opportunity.\u201d<\/p>\n

About Lakefront\u00ae Biotherapeutics<\/p>\n

Lakefront Biotherapeutics (formerly known as Galapagos) is a biotechnology company dedicated to building a differentiated pipeline of medicines for patients with serious diseases in areas of high unmet need. The Company has established a clinical\u2011stage portfolio in immunology and inflammation, anchored by gamgertamig, a potential first\u2011in\u2011class BCMAxCD3 T\u2011cell engager for autoimmune diseases. Backed by deep deal\u2011making expertise, operational flexibility, and a strong capital position, Lakefront identifies, acquires, and advances high\u2011quality assets with clear potential to deliver meaningful patient impact and long\u2011term shareholder value. For more information, visit https:\/\/www.lakefrontbio.com<\/a> or follow us on LinkedIn<\/a> or X<\/a>.<\/p>\n

For further information, contact Lakefront Biotherapeutics:<\/p>\n

Get the latest news
\n

\n delivered to your inbox<\/p>\n

Sign up for The Manila Times newsletters<\/p>\n

By signing up with an email address, I acknowledge that I have read and agree to the Terms of Service<\/a> and Privacy Policy<\/a>.<\/p>\n

Investor Relations <\/p>\n

Sherri Spear<\/p>\n

+1 412 522 6418<\/p>\n

[email\u00a0protected]<\/a><\/p>\n

Forward-looking statements<\/p>\n

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, all of which involve certain risks and uncertainties. These statements are often, but are not always, made through the use of words or phrases such as “believe,\u201d “anticipate,\u201d “expect,\u201d “intend,\u201d “plan,\u201d “seek,\u201d “upcoming,\u201d “future,\u201d “estimate,\u201d “may,\u201d “will,\u201d “could,\u201d “would,\u201d “potential,\u201d “forward,\u201d “goal,\u201d “next,\u201d “continue,\u201d “should,\u201d “encouraging,\u201d “aim,\u201d “progress,\u201d “remain,\u201d “explore,\u201d and “further,\u201d as well as similar expressions. These statements include, but are not limited to, statements regarding Lakefront\u2019s plans to appoint a new director to the Board of Directors. Lakefront cautions the reader that forward-looking statements are based on management\u2019s current expectations and beliefs and are not guarantees of future performance. Forward-looking statements may involve known and unknown risks, uncertainties and other factors which might cause actual events, financial condition and liquidity, performance, or achievements, or the industry in which we operate, to be materially different from any historic or future results, financial conditions, performance or achievements expressed or implied by such forward-looking statements. In addition, even if Lakefront\u2019s results, performance, financial condition and liquidity, and the development of the industry in which Lakefront operates are consistent with such forward-looking statements, they may not be predictive of results or developments in future periods. These risks, uncertainties, and other factors include, without limitation, the risk that Lakefront will encounter challenges appointing or retaining a new director and that Lakefront may not be able to realize the expected benefits from the appointment of a new director. A further list and description of these risks, uncertainties, and other factors can be found in Lakefront\u2019s filings and reports with the Securities and Exchange Commission (“SEC\u201d), including in Lakefront\u2019s most recent annual report on Form 20-F filed with the SEC and Lakefront\u2019s subsequent filings and reports filed with the SEC. Given these risks and uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements. In addition, even if the result of Lakefront\u2019s operations, financial condition and liquidity, or the industry in which we operate, are consistent with such forward-looking statements, they may not be predictive of results, performance or achievements in future periods. These forward-looking statements speak only as of the date of publication of this release. We expressly disclaim any obligation to update any such forward-looking statements in this release to reflect any change in Lakefront\u2019s expectations or any change in events, conditions or circumstances, unless specifically required by law or regulation.<\/p>\n

Attachment<\/p>\n

Lakefront Announces Paulo Fontoura has Resigned from its Board following his Appointment as Global Head of R&D at Sanofi<\/a><\/p>\n

\"\"<\/p>\n","protected":false},"excerpt":{"rendered":"Mechelen, Belgium; July 13, 2026, 22:01 CET; Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) today announced that following…\n","protected":false},"author":2,"featured_media":50877,"comment_status":"","ping_status":"","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[12983],"tags":[23626,33218,7079,6222,10938,19109,27092,9970,2817,3043,10475,33217,20350,33215,3026,27266,18186,33216,13012],"class_list":["post-50876","post","type-post","status-publish","format-standard","has-post-thumbnail","category-sanofi","tag-announces","tag-appointment","tag-as","tag-at","tag-board","tag-following","tag-fontoura","tag-from","tag-global","tag-has","tag-head","tag-his","tag-its","tag-lakefront","tag-of","tag-paulo","tag-rd","tag-resigned","tag-sanofi"],"_links":{"self":[{"href":"https:\/\/www.europesays.com\/france\/wp-json\/wp\/v2\/posts\/50876","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.europesays.com\/france\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.europesays.com\/france\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/france\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/france\/wp-json\/wp\/v2\/comments?post=50876"}],"version-history":[{"count":0,"href":"https:\/\/www.europesays.com\/france\/wp-json\/wp\/v2\/posts\/50876\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.europesays.com\/france\/wp-json\/wp\/v2\/media\/50877"}],"wp:attachment":[{"href":"https:\/\/www.europesays.com\/france\/wp-json\/wp\/v2\/media?parent=50876"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.europesays.com\/france\/wp-json\/wp\/v2\/categories?post=50876"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.europesays.com\/france\/wp-json\/wp\/v2\/tags?post=50876"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}